ABEONA THERAPEUTICS INC. Unrealized Gain (Loss) on Derivatives
ABEONA THERAPEUTICS INC. (ABEO) reported Unrealized Gain (Loss) on Derivatives of $0 for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2015-03-31
- ABEONA THERAPEUTICS INC. unrealized gain (loss) on derivatives for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- ABEONA THERAPEUTICS INC. unrealized gain (loss) on derivatives for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
- ABEONA THERAPEUTICS INC. unrealized gain (loss) on derivatives for the quarter ending 2014-06-30 was $0.00, a 100.00% decline year-over-year.
- ABEONA THERAPEUTICS INC. unrealized gain (loss) on derivatives for the quarter ending 2014-03-31 was $0.00.
- ABEONA THERAPEUTICS INC. unrealized gain (loss) on derivatives for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- ABEONA THERAPEUTICS INC. unrealized gain (loss) on derivatives for fiscal 2013 was $271.00K, a 78.07% decline from fiscal 2012.
- ABEONA THERAPEUTICS INC. unrealized gain (loss) on derivatives for fiscal 2012 was $1.24M, a 65.47% decline from fiscal 2011.
- ABEONA THERAPEUTICS INC. unrealized gain (loss) on derivatives for fiscal 2011 was $3.58M.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $0.00 derived: sum of 2 quarters · filed 2015-03-31 | $0.00 derived: sum of 3 quarters · filed 2015-03-31 | $0.00 10-K · filed 2015-03-31 |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-14 | $0.00 derived: sum of 2 quarters · filed 2014-11-14 | $0.00 10-Q · filed 2014-11-14 | $131.00K derived: sum of 4 quarters · filed 2015-03-31 |
| 2014-06-30 | $0.00 10-Q · filed 2014-08-14 | $0.00 10-Q · filed 2014-08-14 | $131.00K derived: sum of 3 quarters · filed 2015-03-31 | $299.00K derived: sum of 4 quarters · filed 2015-03-31 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-12 | $131.00K derived: sum of 2 quarters · filed 2015-03-31 | $299.00K derived: sum of 3 quarters · filed 2015-03-31 | $518.00K derived: sum of 4 quarters · filed 2015-03-31 |
| 2013-12-31 | $131.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $299.00K derived: sum of 2 quarters · filed 2015-03-31 | $518.00K derived: sum of 3 quarters · filed 2015-03-31 | $271.00K 10-K · filed 2015-03-31 |
| 2013-09-30 | $168.00K 10-Q · filed 2014-11-14 | $387.00K derived: sum of 2 quarters · filed 2014-11-14 | $140.00K 10-Q · filed 2014-11-14 | $140.00K derived: sum of 4 quarters · filed 2014-11-14 |
| 2013-06-30 | $219.00K 10-Q · filed 2014-08-14 | -$28.00K 10-Q · filed 2014-08-14 | -$28.00K derived: sum of 3 quarters · filed 2014-08-14 | $36.00K derived: sum of 4 quarters · filed 2014-08-14 |
| 2013-03-31 | -$247.00K 10-Q · filed 2014-05-12 | -$247.00K derived: sum of 2 quarters · filed 2014-05-12 | -$183.00K derived: sum of 3 quarters · filed 2014-05-12 | $248.00K derived: sum of 4 quarters · filed 2014-05-12 |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26 | $64.00K derived: sum of 2 quarters · filed 2014-03-26 | $495.00K derived: sum of 3 quarters · filed 2014-03-26 | $1.24M 10-K · filed 2014-03-26 |
| 2012-09-30 | $64.00K 10-Q · filed 2013-11-14 | $495.00K derived: sum of 2 quarters · filed 2013-11-14 | $1.24M 10-Q · filed 2013-11-14 | |
| 2012-06-30 | $431.00K 10-Q · filed 2013-08-14 | $1.17M 10-Q · filed 2013-08-14 | ||
| 2012-03-31 | $741.00K 10-Q · filed 2013-05-15 | |||
| 2011-12-31 | $3.58M 10-K · filed 2013-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |